NCT06900010 A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease
| NCT ID | NCT06900010 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shandong First Medical University |
| Condition | Autoimmune Bullous Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-04-22 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 30 participants in total. It began in 2025-04-22 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Eligibility Criteria
Inclusion Criteria: * 1\. Confirmed diagnosis of autoimmune bullous disease； * 2\. Age ≥18 years, regardless of gender； * 3\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements. Exclusion Criteria: * 1\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation； * 2\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy； * 3\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336； * 4\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.
Contact & Investigator
Furen Zhang
PRINCIPAL INVESTIGATOR
Dermatology Hospital affiliated to Shandong First Medical University
Frequently Asked Questions
Who can join the NCT06900010 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Autoimmune Bullous Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06900010 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06900010 currently recruiting?
Yes, NCT06900010 is actively recruiting participants. Contact the research team at splcsy@126.com for enrollment information.
Where is the NCT06900010 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06900010 clinical trial?
NCT06900010 is sponsored by Shandong First Medical University. The principal investigator is Furen Zhang at Dermatology Hospital affiliated to Shandong First Medical University. The trial plans to enroll 30 participants.